drugset
Drugs / Tetravalent Dengue Vaccine (TDV)
last change Jun 2026 re-read 3 minutes ago

Tetravalent Dengue Vaccine (TDV)

also known as TAK-003

Vaccine

Developed for
dengue disease
Investigated by
Takeda

Trials 2

today NCT07047521 · Ph 3 NCT02747927 · Ph 3
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07047521 Nov 2025 → Jun 2026 overdue dengue disease Takeda Active not recruiting No outcome recorded
Phase 3 NCT02747927 Apr 2016 → Jul 2018 — Takeda Completed Met primary

Press releases naming this drug 2 releases

DateIssuerRelease
2022-11-22 Takeda Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration takeda.com ↗
2016-09-07 Takeda Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) takeda.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Tetravalent Dengue Vaccine (TDV) ClinicalTrials.gov intervention name — accepted as the source's own label NCT07047521 ↗
1

NCT02747927 ↗
Known as TAK-003 “the tetravalent dengue vaccine TAK-003” PMID 40099800 ↗ Mar 2025
Modality Vaccine “live-attenuated tetravalent dengue vaccine (TAK-003)” PMID 38995684 ↗ Feb 2025
Route Subcutaneous “TDV 0.5 mL subcutaneous injection” NCT02747927 ↗